Nuvectis Pharma to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

Fort Lee, NJ , Oct. 07, 2024 (GLOBE NEWSWIRE) — Nuvectis Pharma, Inc. (NASDAQ: NVCT) (“Nuvectis” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that management will participate in a panel discussion on innovative therapies for solid tumors at the 3rd Annual ROTH Healthcare Opportunities Conference taking place on October 9, 2024 in New York, NY.

Event Annual ROTH Healthcare Opportunities Conference
Panel Title Innovative Therapies for Solid Tumors
Date and Time October 9, 2024, 12:30 pm ET

About Nuvectis Pharma, Inc.

Nuvectis Pharma, Inc. is a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. The Company is currently developing two clinical-stage drug candidates, NXP800 and NXP900. NXP800 is an oral small molecule GCN2 activator currently in a Phase 1b clinical trial for the treatment for platinum resistant, ARID1a-mutated ovarian carcinoma and in an Investigator-sponsored clinical trial for the treatment of cholangiocarcinoma. The U.S. Food and Drug Administration granted Fast Track Designation to the NXP800 development program in platinum resistant, ARID1a-mutated ovarian carcinoma, and Orphan Drug Designation for the treatment of cholangiocarcinoma and ARID1a-deficient ovarian, fallopian tube, and primary peritoneal cancers. NXP900 is an oral small molecule inhibitor of the SRC Family of Kinases (SFK), including SRC and YES1. NXP900 has a unique mechanism of action in that it inhibits both the catalytic and scaffolding functions of the SRC kinase thereby providing complete shutdown of the signaling pathway. NXP900 is currently in a Phase 1a dose escalation study.

Company Contact
Ron Bentsur
Chairman, Chief Executive Officer and President
201-614-3151
rbentsur@nuvectis.com

Media Relations Contact
Christopher M. Calabrese
LifeSci Advisors
Tel: 917-680-5608
ccalabrese@lifesciadvisors.com

 

Staff

Recent Posts

Greenway Health Announces New Chief Information Security Officer

Paul Ford brings extensive leadership and expertise in cybersecurity, further strengthening Greenway Health's commitment to…

4 hours ago

BioNJ’s Prestigious Speaker Roster for Its 12th Annual C-Suite Summit

TRENTON, N.J., Oct. 7, 2024 /PRNewswire/ -- BioNJ is hosting its C-Suite Summit this Thursday, October 10,…

4 hours ago

PatientPoint Unveils New Interactive Solution to Streamline Care Team Communication

First of its kind, in-office, digital hub enhances provider efficiency and care team collaboration CINCINNATI,…

4 hours ago

Hospital PMI® at 55%; September 2024 Hospital ISM® Report On Business®

TEMPE, Ariz., Oct. 7, 2024 /PRNewswire/ -- Economic activity in the hospital subsector grew in September…

4 hours ago

Sunwave Health and High Watch Recovery Center/Alina Lodge Announce Strategic Partnership to Revolutionize Behavioral Health Care

DELRAY BEACH, Fla., Oct. 7, 2024 /PRNewswire/ -- Sunwave Health, a leading provider of healthcare…

4 hours ago